La Jolla Pharmaceutical Co
F:LJPP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
H
|
Heineken NV
SWB:HNK1
|
NL |
La Jolla Pharmaceutical Co
Accounts Payable
La Jolla Pharmaceutical Co
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
L
|
La Jolla Pharmaceutical Co
F:LJPP
|
Accounts Payable
$2.1m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-18%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Accounts Payable
$34.7B
|
CAGR 3-Years
11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
23%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Accounts Payable
$715m
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-5%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Accounts Payable
$20.9B
|
CAGR 3-Years
137%
|
CAGR 5-Years
71%
|
CAGR 10-Years
36%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Accounts Payable
$3.9B
|
CAGR 3-Years
134%
|
CAGR 5-Years
91%
|
CAGR 10-Years
48%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Accounts Payable
$6.8B
|
CAGR 3-Years
126%
|
CAGR 5-Years
70%
|
CAGR 10-Years
47%
|
|
La Jolla Pharmaceutical Co
Glance View
La Jolla Pharmaceutical Co. operates as a biopharmaceutical company. The company is headquartered in Waltham, Massachusetts and currently employs 61 full-time employees. Its product pipeline includes GIAPREZA (angiotensin II) and XERAVA (eravacycline). Its GIAPREZA injection is a vasoconstrictor indicated to increase blood pressure in adults with septic or other distributive shocks. The GIAPREZA is used for the treatment of refractory hypotension in adults with septic or other distributive shocks. Its XERAVA is a tetracycline-class antibacterial indicated for the treatment of complicated intra-abdominal infections (cIAI) in adults. Its early-stage clinical development product candidate includes TP-6076 and TP-2846. Its TP-6076 is an IV formulation of a fully synthetic fluorocycline derivative for the treatment of certain multidrug-resistant gram-negative bacteria. Its TP-2846 is an IV formulation of tetracycline for the treatment of acute myeloid leukemia. Its product candidate also includes TP-271.
See Also
What is La Jolla Pharmaceutical Co's Accounts Payable?
Accounts Payable
2.1m
USD
Based on the financial report for Jun 30, 2022, La Jolla Pharmaceutical Co's Accounts Payable amounts to 2.1m USD.
What is La Jolla Pharmaceutical Co's Accounts Payable growth rate?
Accounts Payable CAGR 5Y
-18%
Over the last year, the Accounts Payable growth was 15%. The average annual Accounts Payable growth rates for La Jolla Pharmaceutical Co have been -24% over the past three years , -18% over the past five years .
